What is the appropriate L‑lysine dosing regimen for an adult with recurrent herpes labialis (cold sores) for acute treatment at prodrome and for prophylaxis in someone with ≥ 3 recurrences per year?

L-Lysine Dosing for Recurrent Herpes Labialis

L-lysine is not recommended as first-line therapy for cold sores because current CDC guidelines prioritize proven oral antivirals (valacyclovir, famciclovir, or acyclovir), which have high-quality evidence for efficacy, while lysine has inconsistent and low-quality supporting data. 1

First-Line Treatment: Proven Oral Antivirals

For acute treatment at prodrome or within 24 hours of lesion onset:

• Valacyclovir 2 g twice daily for 1 day is the preferred first-line regimen, reducing median episode duration by 1.0 day compared to placebo 1
• Famciclovir 1500 mg as a single dose is an equally effective alternative with convenient single-day dosing 1
• Acyclovir 400 mg five times daily for 5 days is effective but requires more frequent dosing 1

Critical timing: Treatment must be initiated during the prodromal phase or within 24 hours of symptom onset, as peak viral titers occur in the first 24 hours after lesion onset 1

Suppressive Therapy for Frequent Recurrences (≥6 per year)

For patients with ≥6 recurrences annually:

• Valacyclovir 500 mg once daily (can increase to 1000 mg once daily for very frequent recurrences) 1
• Famciclovir 250 mg twice daily 1
• Acyclovir 400 mg twice daily 1

Daily suppressive therapy reduces recurrence frequency by ≥75% among patients with frequent recurrences 1

L-Lysine: Evidence Summary and Dosing (If Considered)

Why Lysine Is Not First-Line

The evidence for lysine is mixed and of lower quality compared to prescription antivirals:

• One study (1984) showed benefit: 1000 mg daily lysine reduced lesion frequency when serum lysine exceeded 165 nmol/mL 2
• Two controlled trials showed no benefit: Studies using 1000 mg daily 3 and 1200 mg daily (400 mg three times daily) 4 found no substantial effect on recurrence rate, duration, or severity
• A 2017 systematic review concluded: Doses <1 g/day appear ineffective; doses >3 g/day may improve subjective symptoms, but high-quality evidence is lacking 5

If Lysine Is Used Despite Limited Evidence

For prophylaxis (based on available research):

• Minimum effective dose appears to be 1000–1200 mg daily 2, 3, 4
• Doses exceeding 3 g/day may provide greater subjective benefit according to the 2017 review 5
• One uncontrolled study used 312–1200 mg daily in single or multiple doses 6

For acute treatment:

• No high-quality evidence supports lysine for acute episode treatment 4, 5
• The 1984 trial showing no benefit used 400 mg three times daily (1200 mg/day total) 4

Important Caveats for Lysine Use

• Patients with cardiovascular or gallbladder disease should be cautioned about theoretical risks of lysine supplementation 5
• Lysine does not replace antiviral therapy and should not delay initiation of proven treatments 1
• Arginine restriction may be necessary for lysine to be effective, as the arginine-to-lysine ratio affects viral replication 6, 5
• Longer-duration controlled studies of doses >1.2 g/day are needed to definitively establish efficacy 5

Clinical Algorithm

For a patient with ≥3 recurrences per year:

1. Acute episodes: Initiate valacyclovir 2 g twice daily for 1 day at first prodromal symptom 1
2. If ≥6 recurrences per year: Start daily suppressive therapy with valacyclovir 500 mg once daily 1
3. After 1 year of suppression: Consider discontinuation to reassess recurrence frequency, as it decreases over time in many patients 1
4. Lysine supplementation: May be considered as adjunctive therapy (not replacement) at doses ≥1000 mg daily, with realistic counseling that evidence is inconsistent 2, 3, 4, 5

Common Pitfalls to Avoid

• Relying solely on lysine instead of proven antivirals delays effective treatment and prolongs episodes 1
• Starting antiviral treatment too late (after 24 hours) significantly decreases efficacy 1
• Using topical antivirals alone, which provide only modest benefit compared to oral therapy 1
• Failing to counsel patients about trigger avoidance (UV light, stress, fever, menstruation), which can reduce recurrence frequency even without medication 1